^
    Back
    Association details:
    Biomarker:RAS mutation
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Real-world study of the efficacy and safety of bevacizumab for first-line and post-first-line treatment of advanced RAS mutated colorectal cancer

    Excerpt:
    ...6.RAS mutation, regardless of BRAF. ...
    Trial ID:
    ChiCTR2100042553
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)

    Excerpt:
    ...CTP as predictive marker for efficacy measured by progression-free survival`CTP as predictive marker for efficacy measured by overall survival`Tumor vasculature at progression`Subgroup analyses according to the RAS mutation status, BRAF mutation status and VEGF-A level`Local and distant recurrences...
    Trial ID:
    AVA-CTP
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Metformin combined with FOLFIRI+bevacizumab in the second-line treatment of non-diabetic RAS mutant metastatic colorectal cancer: a multi-center, single-arm phase II clinical study

    Excerpt:
    ...Genetically tested as RAS mutant type; 5. ...
    Trial ID:
    ChiCTR2000037943
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

    Excerpt:
    ...Ras/Braf mutation analysis at enrollment identifies Ras/Braf status as either the wild type or mutant type....
    Trial ID:
    QUATTRO-II
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer

    Excerpt:
    ...Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on overall objective response`Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on surgical resection rate`Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on survival`Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on progression free survival...
    Trial ID:
    AVAMET
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

    Excerpt:
    ...Progression-free survival: native versus mutated K-RAS; tumour assessments according to RECIST criteria...
    Trial ID:
    NCT01338558
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)

    Excerpt:
    ...Percentage of Participants by Prognostic Factors`Percentage of Participants by Carcinoembryonic Antigen Tumor Marker`Percentage of Participants by Cancer Antigen 19-9 Tumor Marker`Percentage of Participants by Eastern Cooperative Oncology Group (ECOG) Performance Status`Percentage of Participants by Comorbidity Index as per Carlson Method`Percentage of Participants by RAS Mutation Status`Percentage of Participants by Cancer Metastasation Status`Percentage of Participants According to Previous Treatment Regimen of Bevacizumab`Progression-Free Survival as Assessed by RECIST (Overall)`Overall Survival in Daily Routine Practice`Overall Survival in Defined Participant Subgroups in Daily Routine Practice`Percentage of Participants Showing Overall Response in Daily Routine Practice as Assessed by RECIST`Number of Treatment Application Schemes of Bevacizumab Daily Routine Practice`Number of Participants With Adverse Event`Number of Participants With Reason for Bevacizumab Treatment Modifications and Discontinuation in Defined Participant Subgroups`Total Cumulative Therapy Dose of Bevacizumab`Percentage of Participants With Treatment Success`Percentage of Participants With Resection`Number of Physicians Satisfied With Treatment`Percentage of Participants Without Resection by Reason`Percentage of Participants With Follow-Up therapy`Percentage of Participants in Defined Participant Subgroups Showing Overall Response in Daily Routine Practice as Assessed by RECIST...
    Trial ID:
    NCT01775644
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients

    Excerpt:
    ...Overall survival`Overall response rate`Time to onset of response`Duration of response`Treatment cycles number`Number of patients who need medicine dose reduction`adverse events`Prognostic and predictive factor of Circulating endothelial cells (CEC) and circulating tumors cells (CTC) baseline and after 3 cycle`Prognostic factor of the K-Ras gene mutation...
    Trial ID:
    NCT00335595
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

    Excerpt:
    ...- RAS mutations...
    Trial ID:
    REVOLUTION
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

    Excerpt:
    ...RAS/BRAF mutation status and UGT1A1*28/*6 gene polymorphism typing should be determined before enrollment....
    Trial ID:
    NCT05969899
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

    Excerpt:
    ...Age 18-75 years; Histologically proven colorectal adenocarcinoma; Simultaneous liver-limited metastases; Initially unresectable liver metastases determined by a local MDT; Life expectancy of > 3 months; RAS mutation and BRAF V600E wild-type; ECOG 0-1; Available PET/CT imaging before treatment; Available colonoscopy biopsy specimens before treatment...
    Trial ID:
    NCT05354674
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer

    Excerpt:
    ...Time to event outcome measure (death), measured in days from cycle 1 day 1`To utilize CT or PET/CT scans to assess overall tumor response rate (complete and partial response) and evaluate disease progression in subjects with advanced or recurrent RAS mutant colorectal cancer treated with the combination of ascorbic acid and FOLOX/FORFIRI +/- bevacizumab versus treatment with FOLFOX/FORFIRI +/- bevacizumab alone`Assessment of the percentage of participants with adverse events and serious adverse events observed throughout the study, and for 30 days after cessation of study treatment...
    Trial ID:
    VITALITY
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

    Excerpt:
    ...- RAS mutation and BRAF V600E wild-type;...
    Trial ID:
    BECOME2
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients

    Excerpt:
    ...age 18-75 years, histologically proven colorectal adenocarcinoma, with liver-dominant disease, a life expectancy of > 3 months, ras mutation, unresectable simultaneous liver metastasis, ECOG 0-1, written informed consent for participation in the trial....
    Trial ID:
    NCT04525313
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

    Excerpt:
    ...With evidence of tumor RAS gene mutant status; 5....
    Trial ID:
    NCT01972490
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Refractory advanced colorectal cancer in the treatment with integrated traditional Chinese and western medicine: a multi-center clinical study

    Excerpt:
    ...RAS mutation (including KRAS, NRAS and HRAS); 5. ...
    Trial ID:
    ChiCTR2200065434
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Establishment and validation of therapeutic effect prediction model of first line treatment of bevacizumab combined with mFOLFOX6 in Ras mutant colorectal cancer patients with liver metastasis

    Excerpt:
    ...3) Ras mutation. ...
    Trial ID:
    ChiCTR2000036551
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Clin Pharm Ther
    Title:

    Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer

    Published date:
    02/25/2022
    Excerpt:
    CONTRADICTING EVIDENCE: The median progression-free survival (mPFS)of patients was 9.0 months (95% CI 8.0-10.0) in the observation group and 7.2 months (95% CI 6.0-8.4) in the control group, with a statistically significant difference (p < 0.05)….Bevacizumab combined with capecitabine was well tolerated and contributed to a longer PFS time than capecitabine alone, and it is worthy of popularization in clinical practice.
    Secondary therapy:
    capecitabine
    DOI:
    10.1111/jcpt.13576
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Br J Cancer
    Title:

    Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

    Published date:
    01/06/2022
    Excerpt:
    PRODIGE 14 was an open-label, multicenter, randomised Phase 2 trial. CRC patients with initially defined unresectable liver-only metastases received either, 2-CTx (FOLFOX or FOLFIRI) or 3-CTx (FOLFIRINOX), plus bevacizumab/cetuximab by RAS status. We failed to increase from 50 to 70% the R0/R1 liver-resection rate with the use of 3-CTx combined with bevacizumab or cetuximab by RAS status in CRC patients with initially unresectable liver metastases.
    Secondary therapy:
    FOLFIRINOX
    DOI:
    10.1038/s41416-021-01644-y